Skip to main content

Advertisement

Table 1 Characteristics of included studies

From: Efficacy of pentoxifylline treatment for neonatal sepsis: a meta-analysis of randomized controlled studies

NO. Author Pentoxifylline group Control group Jada scores
Number Gestational age (weeks) Male (n) Birth weight (g) Methods Number Gestational age (weeks) Male (n) Birth weight (g) Methods  
1 Shabaan 2015 [21] 60 30.2 ± 2.5 34 1404 ± 417 intravenous pentoxifylline 5 mg/kg/hr. for 6 h on 6 successive days 60 30.1 ± 2.2 44 1370 ± 471 matched placebo 5
2 Akdag 2014 [22] 51 31 (24–42) 29 1490 (620–4580) pentoxifylline 6 mg/kg/h intravenously, over 4 h, daily for three consecutive days 51 31 (25–40) 33 1410 (620–4300) matched placebo 4
3 Adel 2010 [23] 17 35.94 ± 4.04 9 2470 ± 890 pentoxifylline 5 mg/kg/h for 6 h, for 6 successive days 20 36.05 ± 3.2 11 2210 ± 590 matched placebo 4
4 Ali 2006 [24] 25 32–37 950–2580 pentoxifylline 5 mg/kg/h for 6 h, for 3 successive days 25 32–37 1000–2650 matched placebo 3
5 Selim 2004 [29] 13 37.62 ± 2.43 2509 ± 549 initiately 0.5 h before beginning antibiotic therapy and given in a dose of 0.5 mg/kg/h by continuous infusion for 24 h 7 38 ± 2.08 2822 ± 637 matched placebo  
6 Lauterbach 1999 [30] 40 31.6 ± 2.9 23 1690.2 ± 396.5 pentoxifylline 5 mg/kg/h for 6 h, for 6 successive days 38 32.8 ± 3.01 20 1749.8 ± 475.6 matched placebo  
7 Lauterbach 1996 [20] 16 31.54 ± 31 1752.09 ± 483.4 pentoxifylline 5 mg/kg/h for 6 h, for 3 successive days 16 32.35 ± 33 1861.29 ± 511.7 matched placebo